Peptomyc
Pepi Morales Bermudez has a diverse and extensive work experience in the field of clinical research. From 2020 onwards, Pepi has been working as a Clinical Project Lead at Peptomyc. Prior to this, from 2018 to 2020, Pepi held roles at Odonate Therapeutics™, including Regional Director Clinical Operations and Director Clinical Site Relationship Management. Pepi's career in clinical research began in 2004 at SOLTI, where they served as the Technical Director of Clinical Research. Pepi's responsibilities at SOLTI included managing phase III clinical trials on diabetes and cardiovascular diseases, in addition to having a background in Biological Sciences and Medicine.
From 1983 to 1991, Pepi Morales Bermudez attended the Universitat Autònoma de Barcelona, where they obtained a Master of Science (MS) degree in Biology. Later, from 1992 to 1997, they went on to pursue a Doctor of Philosophy (PhD) degree in Medicine at the same university.
This person is not in any teams
Peptomyc
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.